Jeff Jonas

Dr. Jeffrey M.
Jonas, MD, is an Independent Non Executive Director at Compass Pathways Plc, a Chairman at Kenai Therapeutics, Inc., a General Partner at Cure Ventures Management LP, a Chairman at Noema Pharma AG and a Chief Executive Officer at Tortugas Neuroscience, Inc. He is on the Board of Directors at Compass Pathways Plc, Angiocrine Bioscience, Inc. and Pharmaceutical Research & Manufacturers of America.
Dr. Jonas was previously employed as a Chief Executive Officer by Abio-X Holdings, Inc., an Independent Director by PureTech Health Plc, an Independent Director by Generation Bio Co., a President-Regenerative Medicine Division by Shire Plc /Old/, an Executive Vice President by Isis Pharmaceuticals, Inc., a Chief Medical Officer & Executive Vice President by Forest Laboratories, Inc., a Vice President-Research & Clinical Development by Upjohn Laboratories LLC, a President, Chief Executive Officer & Director by AVAX Technologies, Inc., an Independent Director by CARA Therapeutics, Inc., a Chairman, President & Chief Technology Officer by Evogen, Inc., a Chief Resident by Harvard Medical School, a Chief Resident by McLean Hospital, Inc., and a President by Shire Regenerative Medicine, Inc. He also served on the board at Karuna Therapeutics, Inc., Swedish Orphan Biovitrum AB, Decibel Therapeutics, Inc. and SAGE Therapeutics, Inc. He received his undergraduate degree from Amherst College and a doctorate degree from Harvard Medical School.